ADXS Advaxis, Inc.

9.16
+0.23  (2.58%)
Previous Close 8.93
Open 8.86
Price To book 3.00
Market Cap 367.75M
Shares 40,147,000
Volume 461,107
Short Ratio 11.20
Av. Daily Volume 647,736

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2017.
Axalimogene filolisbac
Cervical cancer
Phase 1/2 updated data due 2H 2017.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016. Part B combination portion of trial commenced October 2016. Enrollment to be completed by end of 2017.
ADXS-PSA and Keytruda
Castrate-resistant prostate cancer
Announced Phase 3 first patient dosed - February 6, 2017.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Phase 2 top-line data released October 24, 2016. Second stage was not completed due to the clinical hold in 2015.
Axalimogene filolisbac - GOG 0265 study
Cervical cancer
Phase 1b ongoing.
ADXS-HER2
HER2-driven malignancies - cancer
Phase 2 initiated June 2016. Preliminary update due 2H 2017.
Axalimogene filolisbac
Anal cancer (FAWCETT)

Latest News

  1. Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer
  2. GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer
  3. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : January 26, 2017
  4. New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported
  5. Advaxis, Inc. – Value Analysis (NASDAQ:ADXS) : January 13, 2017
  6. ADVAXIS, INC. Financials
  7. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : January 12, 2017
  8. ADVAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  9. Advaxis Provides 2017 Business Outlook
  10. ADVAXIS, INC. Files SEC form 10-K, Annual Report
  11. ADVAXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  12. Discussion on Advaxis’ ADXS-NEO, ADXS-HOT Programs Held During the International Congress on Immunotherapies in Cancer
  13. Advaxis to Present Data at ImVacS-Immunization and Vaccine Summit on Use of Detoxified Listeriolysin O (dtLLO) as an Effective Adjuvant in Vaccine Formulations
  14. How Advaxis, Inc. (ADXS) Stacks Up Against Its Peers
  15. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : November 22, 2016
  16. INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Advaxis, Inc.
  17. ETF’s with exposure to Advaxis, Inc. : November 11, 2016
  18. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : November 10, 2016
  19. Lifshitz & Miller Law Firm Announces Investigation of Advaxis, Inc., Banc of California, Inc., Biogen Inc., Franklin Resources, Inc., Juniper Pharmaceuticals, Inc., Opus Bank, Taro Pharmaceutical Industries Ltd., and Tyson Foods, Inc.
  20. Advaxis Cervical Cancer Drug Makes Progress (ADXS)